| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Filing example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Ensysce Biosciences, Inc.$0.27
-0.01 (-2.85%)
D 29Pipeline Score Overvalued Biotech · Commercial
Market Cap
4.68 M
EPS
-3.35
P/E Ratio
-
Value Trade
229.35 K
SEC Financials
Q1 2026Dilution Risk
Revenue
961.00 K
R&D Expenses
3.35 M
Operating CF
-3.50 M
Total Assets
2.17 M
Total Liabilities
2.84 M
Equity
-340.04 K
D/E Ratio
12,345
15.18 %
Week
-28.87 %
1 Month
-16.05 %
3 Month
-80.33 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
745.48 K
Monthly Burn
1.17 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
435.44 K
52 Week Range
0.23 - 2.75
% held by Insiders
0.07 %
% held by Institutions
3.17 %
Enterprise Value
3.82 M
Total Shares
9.27 M
Short %
2.37 %
Float Shares
9.16 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ensysce Biosciences, Inc.
199Total events
5Upcoming
29Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
Event history 194
Jun 13, 2026
◆Oral PresentationPresentation
CPDD 88th Annual Meeting presentation by Dr. Lynn Kirkpatrick
substance use disorderssource ↗
Jun 3, 2026
◆Oral PresentationPresentation
Commercial Excellence and AI - Immersion Lab discussions by Mr. Geoff Birkett
pain therapeuticssource ↗
May 7, 2026
◆Oral PresentationPF614Presentation
European Pain Therapeutics Summit presentation on PF614 and PF614-MPAR by Dr. Lynn Kirkpatrick
painsource ↗
May 7, 2026
◆Oral PresentationPF614Presentation
European Pain Therapeutics Summit presentation on PF614 and PF614-MPAR by Dr. Lynn Kirkpatrick
painsource ↗
Apr 7, 2026
▼Equity OfferingCorporate
Closed second tranche of $2 million convertible preferred stock financing
Apr 2026
Mar 23, 2026
◆Oral PresentationPresentation
USASP Annual Scientific Meeting presentation by Dr. William Schmidt
pain therapeuticssource ↗
Mar 2026
▲PublicationPF614Presentation
First peer-reviewed clinical manuscript on MPAR overdose protection published in Journal of Opioid Management
painsource ↗
Feb 25, 2026
◆Pipeline PrioritizationCorporate
Board initiates formal review of strategic alternatives to enhance shareholder value
Drug Pipeline Intelligence
D29
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 33%
Micro Cap (rank 611 of 911)
Percentile RankEnsysce Biosciences, Inc. faces pipeline headwinds (29/100), with $495M risk-adjusted pipeline value, led by PF614 in Acute Pain (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PF614 Small molecule | Postoperative Pain, Acute | Phase 3 | NCT06602271 | 76% | $460M | RECRUITING | 320 | STALLED | B (67) | Nov 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PF614-MPAR BreakthroughFast Track | opioid overdose protection | Phase 1 | 2026-03-03 | PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. Read More | Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology Read More | |
PF614-MPAR BreakthroughFast Track | opioid overdose protection | Phase 1 | 2026-03-03 | PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. Read More | Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology Read More | |
PF614-MPAR BreakthroughFast Track | opioid overdose protection | Phase 1 | 2026-03-03 | PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. Read More | Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENSC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ENSC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENSC▲ +6.3%on this news
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences has enrolled its first patient in the final phase of the PF614-MPAR-102 clinical study, which evaluates a novel opioid designed to prevent overdose. This first-in-class therapy utilizes a unique mechanism to control opioid release, aiming to enhance patient safety. The study is backed by the National Institute on Drug Abuse and follows previous positive data from earlier trials.
Read more →ENSCEnsysce Biosciences Reports First Quarter 2026 Financial Results ~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR ; Patent Estate E
Ensysce Biosciences reported significant operational progress for Q1 2026, including securing IRB approval for the final stage of its PF614-MPAR-102 study and achieving 50% enrollment in its pivotal Phase 3 trial. The company also published its first peer-reviewed data supporting its overdose protection technology in opioids. Additionally, Ensysce expanded its patent portfolio, enhancing its position in both opioid and ADHD markets. A formal review of strategic alternatives, including potential partnerships, is underway to accelerate the development of its therapeutic platforms.
Read more →ENSCEnsysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs ~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesi
Ensysce Biosciences announced the closing of a second financing round of $2 million as part of a broader agreement worth up to $20 million. This funding will support its flagship analgesic programs focusing on developing tamper-proof and abuse-resistant pain management solutions. The company aims to revolutionize the treatment landscape for severe pain using its proprietary platforms. CEO Kirkpatrick emphasized the investor confidence and the need for transformative treatments in pain management.
Read more →ENSCEnsysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results ~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA /
Ensysce Biosciences recently reported its financial results for Q4 and full year 2025, highlighting notable progress in clinical trials and regulatory engagement for PF614. The company initiated its Phase 3 trial and received supportive feedback from the FDA regarding its development pathway for PF614-MPAR. Despite facing increased operational losses, Ensysce has strengthened its intellectual property, expanded its pipeline, and improved overall financial stability. The firm continues to focus on developing safer opioid medications while addressing the challenge of opioid abuse.
Read more →ENSCEnsysce Biosciences Initiates Live “Ask Me Anything” (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences has launched a live 'Ask Me Anything' session to engage with stakeholders about its strategic plans and the PF614 program. CEO Dr. Lynn Kirkpatrick highlighted the program's commercial potential and the company's commitment to transparency. Key topics included the timeline for PF614-301 and efforts to mitigate regulatory risks. The session demonstrated strong community interest and provided insights into the company's future direction.
Read more →ENSC▼ -15%on this newsshared move
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Ensysce Biosciences has published the first peer-reviewed clinical study on its MPAR technology, which provides overdose protection for opioid users. The study, featured in the Journal of Opioid Management, highlights the effectiveness of PF614-MPAR in maintaining therapeutic opioid levels while preventing overdose. This innovation represents a significant advancement in pain management and opioid safety.
Read more →ENSCEnsysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences has initiated a review of strategic alternatives aimed at enhancing shareholder value and advancing its proprietary technologies. The review may include partnerships, licensing, and other corporate transactions. CEO Dr. Lynn Kirkpatrick emphasized the potential of their technologies to improve opioid safety. However, no specific outcomes or timelines have been established.
Read more →ENSC▼ -6.6%on this newsshared move
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences has been invited to participate in several upcoming scientific and industry events, where it will present its innovative pain therapeutics and discuss its TAAP and MPAR programs. Key executives will share insights on the company's approach to reducing opioid abuse and overdose risks. These engagements aim to enhance collaboration within the clinical and scientific communities.
Read more →ENSC▼ -8.7%on this news· ran to -23% by day 3
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences has announced that it has enrolled 50% of subjects for interim review in its pivotal Phase 3 trial of PF614, a next-generation opioid aimed at treating severe acute pain. The trial is being conducted across three U.S. sites and aims to evaluate PF614's efficacy and safety post-abdominoplasty. The drug incorporates built-in abuse protection to enhance patient safety.
Read more →ENSCEnsysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences has received a Notice of Allowance for a new patent covering its MPAR® overdose protection technology, extending patent protection through 2042. This technology, which has received Breakthrough Therapy Designation from the FDA, aims to mitigate the effects of opioid overdoses. Ensysce is also exploring its application for other drug classes, enhancing safety in pain management.
Read more →ENSCEnsysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs ~Funding supports Phase 3 clinical development of PF614 and continued innovation in a
Ensysce Biosciences, Inc. has announced the closing of a $4 million financing round, which could lead to an additional $16 million to support its Phase 3 clinical development of PF614, an analgesic aimed at treating severe pain. The funding reflects strong investor confidence in the company's innovative pain management solutions. Ensysce aims to disrupt the current analgesic market with unique tamper-proof opioids designed to reduce the risks of drug abuse and overdose. While the financial backing provides a pathway to market readiness within 18-24 months, there are inherent risks associated with clinical success and regulatory approvals.
Read more →ENSCEnsysce Biosciences Reports Third Quarter 2025 Financial Results ~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions
Ensysce Biosciences has reported its financial results for the third quarter of 2025, marking significant progress in its clinical programs. The company initiated its Phase 3 trial for PF614 and received Breakthrough Therapy designation from the FDA for the PF614-MPAR program. Despite substantial operational advancements, Ensysce reported a net loss of $3.7 million and a decrease in revenue from grants. The company continues to focus on developing next-generation opioids while navigating the financial challenges typical for a clinical-stage biotech.
Read more →ENSCEnsysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Appr
Ensysce Biosciences has reported its financial results for Q2 2025 and announced the initiation of a pivotal Phase 3 trial for its opioid therapy candidate, PF614. The trial aims to validate PF614's efficacy while providing built-in abuse deterrence. The company received a $5.3 million installment from NIDA to support its overdose protection program, and has successfully enrolled participants for Part 2 of the PF614-MPAR-102 study. Despite a net loss of $1.7 million, Ensysce continues to push forward in redefining pain management with innovative therapeutic solutions.
Read more →ENSC▼ -5.5%on this news
Ensysce Biosciences Reports First Quarter 2025 Financial Results Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection S
Ensysce Biosciences announced its first-quarter financial results for 2025, highlighting significant advancements in its opioid use disorder treatment candidate, PF9001, which received a U.S. patent. The company also reported successful initial results from its PF614-MPAR clinical trial, affirming the treatment's overdose protection capabilities. Despite a decrease in cash reserves and continuing net losses, Ensysce sees potential for disruption in the opioid analgesic market through its innovative technologies. Overall, the company remains optimistic about its progress and future regulatory submissions.
Read more →ENSC▲ +96.3%on this news
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. has announced the exercise of certain outstanding warrants, generating approximately $2.2 million in gross proceeds for the company. The funds will be utilized for the continued development of their TAAPTM and MPAR programs, which aim to create safer opioid treatments for severe pain. The company is focused on addressing opioid abuse and overdose issues through its novel approaches. Closing of the offering is expected on April 24, 2025, pending satisfaction of customary closing conditions.
Read more →ENSC▼ -21.2%on this news
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. announced a registered direct offering, securing approximately $1.1 million from the sale of 315,188 shares of common stock at a price of $3.49 per share. The funds will be directed towards the continued development of the company's innovative pain relief programs, TAAPTM and MPAR. The offering is expected to close on or around March 31, 2025, pending customary conditions. The company also issued unregistered series of warrants in conjunction with this offering.
Read more →ENSCEnsysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates
Ensysce Biosciences reported its fourth quarter and full year 2024 financial results, highlighting a strategic partnership to advance the development of its products PF614 and PF614-MPAR. Positive interim results from the PF614-MPAR trial indicate effective overdose protection. The company is preparing for a phase 3 trial of PF614, with plans to submit a New Drug Application in 2026. However, despite progress, the financial report shows a continued net loss, although reduced from the previous year.
Read more →ENSCEnsysce Biosciences Reports Third Quarter 2024 Financial Results Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol t
Ensysce Biosciences reported its third quarter financial results for 2024, highlighting significant progress in the development of its pain relief therapies. The company received a $14 million multi-year grant from NIH to further its PF614-MPAR clinical development and initiated a second trial. Additionally, they submitted the Phase 3 protocol for PF614 to the FDA for review. While the quarter showed a net income driven by grant funding, future losses are expected as they ramp up R&D activities.
Read more →ENSC▼ -34.7%on this news
Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. has announced a successful $5 million registered direct offering to further its clinical development efforts. The offering involves the sale of approximately 3.6 million shares at a price of $0.47 per share, with concurrent agreements to exercise warrants at the same price. The additional capital will be utilized for the development of their proprietary pain management programs. Ensysce's approach aims to reduce the risks associated with opioid use through innovative treatment options.
Read more →ENSCEnsysce Biosciences Reports Second Quarter 2024 Financial Results PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with
Ensysce Biosciences has reported its second quarter 2024 financial results, highlighting the progression of its PF614-MPAR candidate to a Phase 1b study aimed at overdose protection and effective delivery of oxycodone. The company has selected PF9001 as its lead candidate in its opioid use disorder program, supported by NIH funding. Despite ongoing advancements, Ensysce has reported a net loss and a slight decline in cash reserves, raising potential concerns about its financial stability as it prepares for its upcoming Phase 3 trial for PF614.
Read more →ENSCEnsysce Biosciences Regains Compliance with Nasdaq SAN DIEGO, CA /
Ensysce Biosciences, Inc. has announced that it has regained compliance with Nasdaq's equity requirement, ensuring that its common stock can continue trading on Nasdaq's Capital Market. This decision follows the Hearing Panel's determination on February 26, 2024. Ensysce is focused on developing innovative solutions for severe pain relief with reduced risks of opioid abuse and overdose, utilizing its proprietary technology platforms. However, the company faces inherent uncertainties related to its clinical programs and the potential for future regulatory challenges.
Read more →ENSC▲ +11.6%on this news
Ensysce Biosciences Reports First Quarter 2024 Financial Results PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIE
Ensysce Biosciences has reported its first-quarter financial results for 2024, highlighting progress in its clinical programs and financial improvements. The company received Breakthrough Therapy designation from the FDA for PF614-MPAR, which is expected to expedite its clinical development. With a focus on initiating Phase 3 trials in late 2024, Ensysce aims to demonstrate the potential of its innovative opioid products while navigating financial challenges, including a rise in net loss and decreased grant funding.
Read more →ENSC▲ +5.8%on this news
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results ~ Corporate Update Call to be Held Thursday
Ensysce Biosciences reported its financial results for Q4 and full year 2023, highlighting significant operational and clinical progress, particularly for its lead product PF614. The company received Breakthrough Therapy designation from the FDA for PF614-MPAR, facilitating its clinical advancement. They demonstrated a reduced net loss and are set to initiate Phase 3 trials in late 2024. However, the company experienced a decrease in cash reserves and federal grant funding.
Read more →ENSC▼ -24.6%on this news
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. has announced the successful exercise of warrants that will generate approximately $4.7 million in gross proceeds. The funds will be primarily allocated towards preparation for Phase 3 clinical studies of its lead candidate, PF614, and to repay existing debts. The company aims to enhance drug safety with its unique technology platforms designed to minimize abuse and overdose risks associated with prescription medications.
Read more →ENSC▼ -7.5%on this news
Ensysce Biosciences Postpones Special Meeting of Stockholders to
Ensysce Biosciences has postponed its Special Meeting of Stockholders to December 29, 2023, due to insufficient quorum. The meeting was originally scheduled for December 20, 2023. Stockholders who previously submitted proxies do not need to take action, and those holding shares as of October 30, 2023, can still participate. Ensysce continues to solicit votes and plans to discuss various proposals during the meeting. The company's focus remains on developing safer prescription drugs to minimize abuse and overdose risks.
Read more →ENSCEnsysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing ~ Additional Funding from Investors Validates Company's Mission ~
Ensysce Biosciences has successfully completed a $1.7 million financing through the issuance of convertible notes and warrants. The funding will enhance the company's ability to advance its lead product, PF614, and support regulatory milestones. Ensysce's technologies aim to deliver safer prescription drug options by addressing opioid misuse. However, the company may face challenges related to funding its ongoing operations and the timeline for product approval.
Read more →ENSC▼ -6.6%on this news
Ensysce Biosciences Reports Third Quarter 2023 Financial Results ~ PF614-201 Clinical Study Results Expected by End of Year ~
Ensysce Biosciences has released its financial results for the third quarter of 2023, reporting significant milestones towards commercializing its lead product, PF614. The company received Institutional Review Board approval to initiate clinical trials and engaged a strategic advisory group to enhance partnering opportunities. Despite a notable reduction in net loss compared to the previous year, the company faces ongoing financial challenges, including high operating expenses and decreasing cash reserves. Positive expectations surround the upcoming PF614-201 clinical study results, which are anticipated by the end of December 2023.
Read more →ENSC▼ -7.1%on this news· ran to -20% by day 3
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing ~ Additional Funding from Investor Cohort Validates Company's Mission ~
Ensysce Biosciences, Inc. has secured $1.7 million in financing through senior secured convertible notes, enabling further development of its innovative technologies aimed at improving prescription drug safety. The funding will specifically assist in completing a time of onset study and meeting regulatory milestones for its lead product, PF614. The investment has been well-received by the market, validating the company's mission to provide safer pain relief options. An initial closing is planned before October 26, 2023, with further funding anticipated under similar terms.
Read more →ENSCEnsysce Biosciences Reports Second Quarter 2023 Financial Results ~ Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol ~
Ensysce Biosciences announced its second quarter financial results, highlighting significant progress towards the Phase 3 evaluation of PF614 following the recent IRB approval of the PF614-201 protocol. The company reports an increase in cash reserves, primarily due to a public offering, and a decrease in R&D expenses compared to the previous year. The data from completed studies presents PF614 as a promising, safer alternative for severe pain management with reduced abuse potential. Ensysce's continued advancements signify a potential shift in opioid treatment approaches amidst the ongoing opioid crisis.
Read more →ENSCBiosciences Regains Compliance with Nasdaq
Ensysce Biosciences, Inc. has received notice from Nasdaq confirming that it has regained compliance with the equity requirement, allowing its common stock to continue trading on Nasdaq's Capital Market. The company is focusing on developing safer prescription drugs through its proprietary technology platforms, aiming to address issues related to drug abuse and overdose. However, its product candidates are still undergoing clinical trials and have not yet been approved for use, facing various risks associated with drug development.
Read more →ENSCEnsysce Biosciences, Inc. Announces Closing of $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. has closed a $7 million public offering of common stock and warrants, intended to further the clinical development of its product candidates. The offering included a total of 1,800,876 shares at a price of $3.887 per share, alongside Series A-1 and Series A-2 warrants. Proceeds will be utilized for working capital and general corporate purposes. The SEC approved the registration statement for this offering on May 9, 2023.
Read more →ENSC▼ -28.4%on this news· ran to -50% by day 3
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results ~ Corporate Update Call to be Held Tuesday
Ensysce Biosciences has reported its financial results for Q4 and the full year of 2022, highlighting significant advances in its clinical programs aimed at pain management using its PF614 and PF614-MPAR products. The company completed enrollment in its first PF614-MPAR study and finished two human abuse potential studies for PF614, moving closer to Phase 3 trial plans. Despite these advancements, Ensysce faced increased net losses and operating expenses which raised concerns about its financial stability and reliance on future funding and trial successes.
Read more →ENSC▼ -8.6%on this news
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering FEBRUARY 03, 2023 8:00AM EST SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, Inc. has announced a registered direct offering of 3,571,431 shares of its common stock, expected to raise approximately $3 million. Each share will be sold at a price of $0.84, with warrants also being issued for additional shares at $0.715. The company plans to use the proceeds for general corporate purposes, including working capital and repaying debt. The offering is expected to close around February 6, 2023, pending satisfaction of conditions.
Read more →ENSCEnsysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock SAN DIEGO, CA / ACCESSWIRE /
Ensysce Biosciences, a clinical-stage biotech company, announced a dividend distribution of Series A Preferred Stock to holders of its common stock. Each common stockholder will receive 0.001 of a share of the new preferred stock, which will grant substantial voting rights concerning a reverse stock split. The Series A Preferred Stock aims to provide a mechanism for enhanced control over shareholder decisions related to corporate governance. Ensysce is advancing its proprietary technologies to produce safer prescription medications, emphasizing its commitment to reducing drug abuse and overdose risks.
Read more →ENSCEnsysce Biosciences Announces Pricing of $4.1 Million Public Offering SAN DIEGO, CA / ACCESSWIRE /
Biosciences Announces Pricing of $4.1 Million Public Offering DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve presc
Read more →ENSCEnsysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 ~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~ San Diego, CA (
Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 Acute pain indication may be appropriate, with potential to significantly shorten development path ~ Diego, CA (November 14, 2022) Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC
Read more →ENSCEnsysce Biosciences Announces Results of Special Meeting of Stockholders
Biosciences Announces Results of Special Meeting of Stockholders DIEGO, CA, September 8, 2022 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug saf
Read more →ENSCEnsysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results ~ Corporate Update Call to be Held Wednesday
Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results Corporate Update Call to be Held Wednesday, August 17, 2022 ~ DIEGO, CA, August 11, 2022 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage
Read more →ENSCEnsysce Biosciences Announces Completion of $8 Million Convertible Note Financing
Biosciences Announces Completion of $8 Million Convertible Note Financing DIEGO, August 9, 2022 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug s
Read more →ENSCEnsysce Biosciences Secures $8 Million Convertible Note Financing ~ Additional Funding from Investor Cohort Validates Company's Mission ~
Biosciences Secures $8 Million Convertible Note Financing Additional Funding from Investor Cohort Validates Company's Mission ~ DIEGO, CA, July 1, 2022 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applyin
Read more →ENSCEnsysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results ~ Corporate Update Call to be Held Tuesday
Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results Corporate Update Call to be Held Tuesday, May 17, 2022 ~ DIEGO, CA, May 12, 2022 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech
Read more →ENSCEnsysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101 ~ Results confirmed the safety and longer-lasting profile of PF614 versus OxyContin and provides first human data showing the po
Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101 Results confirmed the safety and longer-lasting profile of PF614 versus OxyContin and provides first human data showing the potential for overdose protection with MPAR~ Announces corporate upda
Read more →ENSCEnsysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing
Read more →ENSCEnsysce Biosciences Announces Participation in the 34th Annual Roth Conference
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse an
Read more →ENSCEnsysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors
SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse an
Read more →ENSCEnsysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting ag
Read more →ENSCEnsysce Biosciences Reminds Stockholders to Vote at Upcoming Special Meeting
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today reminded stockholders to vote
Read more →ENSCEnsysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting ag
Read more →ENSCEnsysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced management’s partic
Read more →ENSCEnsysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may provide new hope for those in severe pain, today announced that it has successfully co
Read more →ENSCEnsysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection
SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced that the first pati
Read more →ENSCEnsysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technologies that may provide new hope for those in severe pain, today announced the completion of a positiv
Read more →ENSCEnsysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Announces Completion of $15 Million Convertible Note Financing
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Announces $15 Million Convertible Note Financing
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose
Read more →ENSCEnsysce Biosciences Announces $15 Million Convertible Note Financing SAN DIEGO, SEPTEMBER 27, 2021 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company wit
Biosciences Announces $15 Million Convertible Note Financing DIEGO, SEPTEMBER 27, 2021 - Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social b
Read more →ENSCEnsysce Biosciences Announces Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose
Read more →ENSCEnsysce Biosciences to Host Satellite Symposium with Dr. Jeffrey Gudin at PAINWeek 2021 on September 9, 2021
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Announces Notice of Allowance from the U.S. Patent and Trademark Office for Patent Entitled “Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof”
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences to Host Virtual Investor Day on July 27, 2021
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose,
Read more →ENSCEnsysce Biosciences Receives Notice of Award for Year Three of Multi-Year NIDA Grant for the Clinical Development of its Next Generation Opioid Products with Overdose Protection
SAN DIEGO, July 08, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or “the Company”), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today annou
Read more →ENSCEnsysce Biosciences to Commence Trading on the OTC on July 1, 2021
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC: LACQ, LACQW) today announced that, in connection with the closing of its previously announced merger with Leisure Acquisition Corp. (“LACQ”), the combined company, Ensysce Bi
Read more →ENSCEnsysce Biosciences to Begin Trading its Common Stock on The Nasdaq Capital Market on July 2, 2021
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW) today announced that the Company will begin trading its common stock under the ticker symbol “ENSC” on The Nasdaq Capital Market and warrants under the t
Read more →ENSCEnsysce Biosciences Announces Closing of Merger Ensysce Common Stock to commence trading under ticker symbol "ENSC" on The Nasdaq Capital Market
Biosciences Announces Closing of Merger Ensysce Common Stock to commence trading under ticker symbol "ENSC" on The Nasdaq Capital Market July 1, 2021. Ensysce Warrants will trade on the OTC Markets under the symbol ENSCW. Ensysce is committed to its mission of reducing the e
Read more →ENSCEnsysce Biosciences Announces Closing of Merger
Ensysce Common Stock to commence trading under ticker symbol “ENSC” on The Nasdaq Capital Market July 1, 2021. Ensysce Warrants will trade on the OTC Markets under the symbol ENSCW. Ensysce is committed to its mission of reducing the economic and social impact of prescription dr
Read more →ENSCLeisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination
Leisure Acquisition Corp. Announces Receipt of and Plan to Appeal Nasdaq Listing Determination NEW YORK, June 1, 2021 (GLOBE NEWSWIRE) - Leisure Acquisition Corp. ("LACQ" or the "Company") (Nasdaq: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purp
Read more →ENSCEnsysce Biosciences’ Covistat Subsidiary “At Home Coronavirus Pill” Commencing to Phase 2 clinical development
NEW YORK and SAN DIEGO, May 07, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce”), which has entered into an agreement for a business combination with Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for th
Read more →ENSCEnsysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
NEW YORK and SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce”) and Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar busines
Read more →ENSCENSYSCE BIOSCIENCES, INC. AND LEISURE ACQUISITION CORP. ANNOUNCE APPOINTMENT OF DAVE HUMPHREY AS CHIEF FINANCIAL OFFICER New York, NY and San Diego, CA, February [18], 2021 - Ensysce Biosciences Inc. ("Ensysce"), a clini
BIOSCIENCES, INC. AND LEISURE ACQUISITION CORP. ANNOUNCE APPOINTMENT OF DAVE HUMPHREY AS CHIEF FINANCIAL OFFICER York, NY and San Diego, CA, February [18], 2021 - Ensysce Biosciences Inc. ("Ensysce"), a clinical stage pharmaceutical company developing medicines for severe pain
Read more →ENSCLeisure Acquisition Corp. [LACQ] Conference Call Regarding Potential Business Combination Between Leisure Acquisition Corp. and Ensysce Biosciences, Inc. Wednesday
Acquisition Corp. [LACQ] Conference Call Regarding Potential Business Combination Between Leisure Acquisition Corp. and Ensysce Biosciences, Inc. Wednesday, February 3, 2021, 11:00 AM ET George Peng; Leisure Acquisition Corp., Chief Financial Officer Daniel Silvers; Leisure A
Read more →ENSCENSYSCE BIOSCIENCES INVESTOR PRESENTATION FEBRUARY 2021 General This presentation (the " Presentation ") has been prepared to assist interested parties in making their own evaluation with respect to a potential business
ENSYSCE BIOSCIENCES INVESTOR PRESENTATION FEBRUARY 2021 General This presentation (the " Presentation ") has been prepared to assist interested parties in making their own evaluation with respect to a potential business combina tio n between Leisure Acquisition Corp. (" Leisure
Read more →ENSCENSYSCE BIOSCIENCES, INC. AND LEISURE ACQUISITION CORP. TO HOST INVESTOR CALL REGARDING BUSINESS COMBINATION ON FEBRUARY 3, 2021 Ensysce Biosciences, a clinical stage biopharmaceutical company with a mission to solve pre
ENSYSCE BIOSCIENCES, INC. AND LEISURE ACQUISITION CORP. TO HOST INVESTOR CALL REGARDING BUSINESS COMBINATION ON FEBRUARY 3, 2021 New York, NY and San Diego, CA, February 2, 2021 / PRNewswire/ -- Leisure Acquisition Corp. (NASDAQ: LACQ, LACQU, LACQW) ("Leisure"), a special purp
Read more →ENSCLEISURE ACQUISITION CORP. ENTERS INTO MERGER AGREEMENT FOR BUSINESS COMBINATION WITH ENSYSCE BIOSCIENCES, INC. Ensysce Biosciences, a clinical stage biopharmaceutical company with a mission to solve prescription drug abu
ACQUISITION CORP. ENTERS INTO MERGER AGREEMENT FOR BUSINESS COMBINATION WITH ENSYSCE BIOSCIENCES, INC. York, NY and San Diego, CA, February 1, 2021 / PRNewswire/ -- Leisure Acquisition Corp. ("Leisure") (NASDAQ: LACQ, LACQU, LACQW), a special purpose acquisition company formed
Read more →ENSCDisclaimer GENERAL This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. The information contained in this presentati
Investor Presentation February 2020 Disclaimer GENERAL This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. The information contained in this presentation (the "Presentation"
Read more →ENSCInvestor Presentation 59 196 February 2020 92 214 173 0 125 245 174 196 211 0 205 151 0 126 153 192 146 146 146 196 0 214 40 0 86 255 255 199 76 0 0 233 117 0 47 76 138 0 221 46 0 86 49 Disclaimer 249 209 190 211 0 211 G
0 221 Exhibit 99.1 46 0 86 49 249 209 190 211 0 211 35 34 34 0 121 59 153 113 0 Investor Presentation 59 196 February 2020 92 214 173 0 125 245 174 196 211 0 205 151 0 126 153 192 146 146 146 196 0 214 40 0 86 255 255 199 76 0 0 233 117 0 47 76 138 0 221 Exhibit 99.1 46 0 86 49
Read more →ENSCInvestor Presentation January 2020
Investor Presentation January 2020 Disclaimer GENERAL This presentation does not constitute an offer or invitation for the sale or purchase of securities and has been prepared solely for informational purposes. The information contained in this presentation (the "Presentation")
Read more →ENSCGAGNIER COMMUNICATIONS Moderator: Lindsay Barber 01-07-20/4:15 p.m. ET Confirmation # 7934997 Page 1 GAGNIER COMMUNICATIONS Moderator: Lindsay Barber
GAGNIER COMMUNICATIONS Moderator: Lindsay Barber 01-07-20/4:15 p.m. ET Confirmation # 7934997 GAGNIER COMMUNICATIONS Moderator: Lindsay Barber All participants are in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the "star
Read more →ENSCGATEWAY CASINOS & ENTERTAINMENT LIMITED
GATEWAY CASINOS & ENTERTAINMENT LIMITED AND LEISURE ACQUISITION CORP. TO HOST INVESTOR CALL REGARDING BUSINESS COMBINATION ON JANUARY 7, 2020 Leading Diversified Canadian Gaming and Entertainment Company, with 25 Properties Across British Columbia and Ontario Operates in Attr
Read more →ENSCGATEWAY CASINOS & ENTERTAINMENT LIMITED AND LEISURE ACQUISITION CORP.
GATEWAY CASINOS & ENTERTAINMENT LIMITED AND LEISURE ACQUISITION CORP. TO COMBINE IN TRANSACTION VALUED AT US$1.1 BILLION (C$1.5 BILLION) Leading Diversified Canadian Gaming and Entertainment Company, with 25 Properties Across British Columbia and Ontario Operates in Attractiv
Read more →ENSCLeisure Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants Commencing
Leisure Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants Commencing December 28, 2017 NEW YORK, NY, December 26, 2017 - Leisure Acquisition Corp. (NASDAQ: LACQU) (the "Company") announced that, commencing December 28, 2017, holders of the units
Read more →ENSCLEISURE ACQUISITION CORP. INDEX TO BALANCE SHEET Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
LEISURE ACQUISITION CORP. INDEX TO BALANCE SHEET Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Audit Committee of the Board of Directors and Shareh
Read more →ENSCLeisure Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering
Leisure Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering NEW YORK, NY, December 1, 2017 - Leisure Acquisition Corp. (the "Company"), a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition,
Read more →Competitive Position
How ENSC ranks across every disease it competes inCompetitive Position is a premium feature
See how ENSC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial